About 50 results
Open links in new tab
  1. The New England Journal of Medicine | Research & Review Articles on ...

    The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...

  2. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …

    Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung …

  3. Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal …

    Mar 1, 2025 · Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy …

  4. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer

    Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured …

  5. A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus ...

    Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. In an open-label, two-period, two-sequence, cross ...

  6. Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...

    Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited.

  7. First-Line Camizestrant for Emerging - The New England Journal of …

    Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced …

  8. The New England Journal of Medicine

    The New England Journal of Medicine

  9. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis

    Apr 8, 2025 · Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple …

  10. Zongertinib in Previously Treated - The New England Journal of Medicine

    Apr 28, 2025 · Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral ...